by Dr. C.H. Weaver M.D. updated 2/2019
A long-term, UCLA-led study finds that those with low- or intermediate-risk disease can safely cut treatment to 4 to 5 days. This study provides the longest follow up to date and confirms previous reports that radiation therapy can be safely and effectively given saving time, reducing costs and improving patient convenience.
The study published in JAMA shows that men with low or intermediate risk prostate cancer can be effectively treated with higher doses of radiation over a shorter period of time and achieve the same outcomes reported with the traditional longer course of radiation treatment.
Men with early stage prostate cancer can currently be treated with surgical prostatectomy, brachytherapy or external beam radiation therapy (EBRT).
Stereotactic body radiotherapy (SBRT) is a specific form of EBRT in which advanced radiotherapy techniques are used to deliver very large doses of radiation over shorter time periods. Stereotactic radiation can be administered over four to five days instead 45 days and has been in use for several years at select institutions.
Many men with low or intermediate risk prostate cancer undergo conventional EBRT which delivers radiation daily for ~ nine weeks. By delivering a higher radiation dose with SBRT treatment can be administered effectively in a much shorter timeframe without additional toxicity and at lower cost. NCCN guidelines since 2014 have stated that SBRT “can be considered as an alternative to conventionally fractionated EBRT regimens at clinics with appropriate technology, physics, and clinical expertise” but longer term follow-up has been lacking.
The report published in JAMA analyzed 2,142 men with low or intermediate risk prostate cancer treated at multiple institutions with SBRT between 2000 and 2012 that have now been followed for an average of ~ 7 years from initiation of treatment.
The recurrence rate for men low risk disease is reported to be 4.5%, and 10.2% for intermediate-risk disease. Although the study did not directly compare SBRT to traditional EBRT these recurrence rates are essentially identical to the 4% to 5% reported for low-risk disease and 10% to 15% percent for intermediate-risk disease.
The current study now provides longer term data regarding the safety and clinical effectiveness of SBRT and represents a more convenient and lower cost alternative for men with low to intermediated risk early stage prostate cancer. of this approach. (1)
Doctors From Spain Have Reported Similar Results
Barcelona, Spain: Radiotherapy given in high doses over a shorter period of time is safe and effective for prostate cancer patients, according to research presented at the ESTRO 37 conference. (2)
The treatment, called ultra hypofractionated radiotherapy, involves hospital treatment every other day for two and half weeks, compared to every week day for eight weeks for standard radiotherapy.
Researchers say this method of giving radiotherapy saves time for patients. It also frees up radiotherapy equipment, saving money and benefiting other patients on the waiting list for treatment.
The study was presented by Professor Anders Widmark, a senior consultant based in the department of radiation sciences and cancer centre at Umeå University, Sweden. He said: “We already know that radiotherapy can destroy cancer cells in the prostate and that it has advantages over surgery and hormone therapy because it is less likely to cause impotence or incontinence. However, radiotherapy requires expensive specialist equipment and patients can end up on a waiting list for treatment.
“Ultrahypofractionated radiotherapy offers a number of practical benefits to patients as well as time and cost-savings for hospitals, so we wanted to test if it is as safe and effective as standard radiotherapy.” The researchers conducted a trial with 1,200 patients who were treated at ten hospitals in Sweden and two in Denmark between July 2005 and November 2015. All had been diagnosed with medium or high-risk cancer, where clinical factors suggest there was a risk that the cancer could spread if it was not treated. None had received treatment to block the male hormone testosterone, which can stimulate prostate cancers to grow.
Half of patients received standard radiotherapy of 39 treatments each with a standard radiation dose of two Gray (Gy), spread over eight weeks (78 Gy in total). The other half received ultrahypofractionated radiotherapy with seven treatments of high dose radiation of 6.1 Gy, every other week day for two and half weeks (42.7 Gy in total). Patients were monitored for an average of five years following treatment to see whether their cancer returned, indicated by a rising level of prostate specific antigen (PSA) and whether they suffered any side-effects.
Researchers found that at five years after treatment 83.8% of patients treated with standard radiotherapy had no signs of their cancer returning and in patients treated with ultrahypofractionated radiotherapy the figure was 83.7%. Although patients who had the ultrahypofractionated treatment suffered slightly worse side-effects at the end of treatment, long-term side-effects were the same as those experienced by patients who had the standard treatment.
Professor Widmark added: “Previous research has already shown that it’s possible to increase individual doses and give them over four to five weeks. Now we have shown that we can condense the therapy further, raising the dose at each hospital visit so that the whole schedule lasts only two and half weeks.
“This is the first large patient trial of this kind and it shows that ultrahypofractionated radiotherapy is just as effective as standard radiotherapy at stopping prostate cancer from returning.
Importantly, it also shows that patients treated in this way do not suffer any more side-effects than those treated with conventional radiotherapy.”
The researchers plan to continue to study the patients in the trial to check whether there are differences in their survival or side-effects in the longer-term. President of ESTRO, Professor Yolande Lievens, head of the department of radiation oncology at Ghent University Hospital, Belgium, said: “Advances in radiotherapy mean that we are better able to locate and target cancers while minimizing damage to nearby organs. In prostate cancer, this can mean men retaining urinary and sexual function. This also means that we can consider giving higher individual doses over a shorter time, as in this study.
“Results of this trial suggests that ultrahypofractionated radiotherapy is equal to conventional radiotherapy. For patients, that could mean they have to spend much less time travelling to and from hospital for treatment. For health services this could help them save resources and get more patients treated sooner.”
- Abstract no: OC-0599, “Ultrahypofractionation for prostate cancer: outcome from the Scandinavian phase 3 HYPORT-PC trial”, Late-breaking abstracts and practice changing trials at 17:05 hrs (CEST) on Monday, 23 April, room 117. The research was funded by the Swedish Research Council and the Swedish Cancer Society.